17 studies on Kisspeptin curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 673 published Kisspeptin COA source records from third-party laboratories, covering 323 publicly attributable vendor identities. Across 619 records with positive numeric purity, the arithmetic mean is 99.54%. 0 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 0 positive purity results are below 90%; 66 records report measured amount more than 10% below the label. The latest recorded test date is 2026-10-14. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
As of 2026-10-18, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 5 mg | $8.50 | $8.50–$8.50 | $1.70 | 1 source · 1 offer |
| 10 mg | $11.25 | $10.50–$12.00 | $1.12 | 2 sources · 2 offers |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. View full price methodology →
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2026-10-14. Aggregate calculated: 2026-10-18T04:29:00.232914+00:00. Calculation time is not a laboratory observation date.
Within that total, 188 source records have unresolved vendor identity. They remain in corpus-level lab evidence and are excluded from named-vendor rankings.
Eligible vendors have at least 2 deduplicated certificates and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and certificate count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes submitted-sample evidence, not every product or shipment, and is not an endorsement.
| Rank | Vendor | Deduplicated certificates | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 11 | 99.74% | 0 of 11 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → | |
| #2 | 15 | 99.53% | 0 of 11 (0.0%) 0 0% / not detected · 0 wrong compound · 4 unclassified | Reveal with Pro → | |
| #3 | 8 | 99.65% | 0 of 8 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → |
Vendor identities are included with Pro. Record counts and lab measurements remain visible.
Recent source records: #119560 (99.23%) · #119611 (99.69%) · #119455 (99.08%) · #118829 (99.17%) · #119302 (99.6%) · #119352 (99.22%)
This comprehensive review significantly advances our understanding of **Kisspeptin's broader metabolic roles beyond reproduction**, suggesting it as a potential therapeutic target for **metabolic disorders**. For bioh…
This research highlights **Kisspeptin-10 as a promising novel therapeutic candidate for ovarian cancer**, offering a potential strategy to combat its aggressive, metastatic nature. By targeting the `SP1-ZEB1-hTERT` ax…
This study highlights **Kisspeptin's potential as a biomarker for predicting COH outcomes and pregnancy success in PCOS patients**. The observed negative correlation between high Kisspeptin levels and top-quality embr…
This study provides critical insights into the dynamic responsiveness of the `HPG axis` to sustained kisspeptin stimulation in men. **Understanding the biphasic response—initial robust stimulation followed by partial …
This research highlights Kisspeptin's potential as a therapeutic agent for mitigating the adverse effects of maternal hypothyroidism on pregnancy outcomes. The restoration of placental mTOR signaling and glucose homeo…
This study provides crucial human data, indicating that an acute intravenous bolus of kisspeptin 112-121 at the tested dose is not effective as a provocative diagnostic test for AVP-D. This finding refines our underst…
This research highlights the Kisspeptin/GPR54 axis as a novel and promising therapeutic target for PAH, a disease with limited effective treatments. By restoring mitochondrial function and normalizing mitophagy in PAS…
Understanding how the HPG axis responds to stimulation like Kisspeptin-10 across different age groups is crucial for addressing age-related reproductive health issues. This research provides foundational insights into…
While this specific study did not yield results, the initial intent highlights the potential scientific interest in Kisspeptin-10 as a modulator of insulin secretion. If future research successfully demonstrates a rol…
Understanding the interplay between reproductive hormones like kisspeptin and metabolic processes could open new avenues for treating metabolic diseases. If kisspeptin were found to positively influence insulin secret…
Free, no account — handy when you're working with Kisspeptin.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account